Urine cell cycle arrest biomarkers distinguish poorly between transient and persistent AKI in early septic shock: a prospective, multicenter study

Table 4 Logistic regression models for the early prediction of persistent AKI

Variable included	Clinical model		Model 2
Variable included	Odds ratio [95% CI]	p value	Odds ratio [95% CI]	p value
Total cohort (n = 184)
Baseline SOFA without renal component	1.16 [1.01–1.33]	0.02	1.16 [1.01–1.32]	0.03
Baseline urine output (ml/kg/h)	0.28 [0.16–0.49]	< 0.001	0.32 [0.19–0.56]	< 0.001
Baseline SCr concentration* (μmol/l)	1.30 [1.08–1.56]	0.005	1.30 [1.08–1.56]	0.006
Baseline [TIMP-2]*[IGFBP7]			1.04 [0.98–1.11]	0.2
Norepinephrine dose at inclusion (μg/kg/min)	2.75 [1.22–6.20]	0.01	2.67 [1.19–6.03]	0.02
AUROC	0.81 [0.74–0.86]		0.81 [0.74–0.86]
Brier score^#	0.18		0.17
Moderate to severe AKI (n = 90)
Baseline SOFA without renal component	1.37 [1.09–1.73]	0.008	1.39 [1.09–1.76]	0.007
Baseline urine output (ml/kg/h)	0.18 [0.07–0.46]	< 0.001	0.19 [0.07–0.49]	< 0.001
Baseline SCr concentration* (μmol/l)	1.22 [0.95–1.58]	0.1	1.23 [0.95–1.59]	0.1
Baseline [TIMP-2]*[IGFBP7]			1.01 [0.95–1.08]	0.7
Norepinephrine dose at inclusion (μg/kg/min)	4.55 [1.12–18.45]	0.03	4.32 [1.07–17.46]	0.04
AUROC	0.86 [0.77–0.92]		0.86 [0.77–0.92]
Brier score^#	0.19		0.19

Data are presented as odds ratios [95% confidence intervals]. The population is divided into two groups according to AKI severity at inclusion
TIMP-2 tissue inhibitor of metalloproteinases-2, IGFBP-7 insulin-like growth factor-binding protein 7, SOFA Sequential Organ Failure Assessment, SCr serum creatinine
*For each 50 μmol/l increase
^#The maximum value expected is 0.25, given the prevalence of persistent AKI in the cohort (46%)

ISSN: 1364-8535